In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has given back its morning gains and is flat at 6,321.8 points.
Four shares that haven’t let this hold them back are listed below. Here’s why they are starting the week with a bang:
The Northern Star Resources Ltd (ASX: NST) share price has surged 17% higher to $8.15 after the gold miner announced the US$260 million acquisition of the high grade Pogo underground gold mine in Alaska. According to the release, Pogo is expected to add 250,000 to 260,000 ounces of gold to the company’s FY 2019 production. Management will partly fund the acquisition with the $175 million successfully raised via a placement to institutional investors at an average price of $6.70 per share.
The Pro Medicus Limited (ASX: PME) share price is up over 6% to $10.82. This morning the healthcare technology company released an investor presentation which reemphasised its strong long-term growth prospects and opportunities to leverage artificial intelligence. I think Pro Medicus is one of the most promising shares in the healthcare sector and well worth taking a closer look at.
The ResApp Health Ltd (ASX: RAP) share price has rocketed 25.5% higher to 24.5 cents after announcing the top line results from its Breathe Easy paediatric double-blind, prospective clinical study. The study, which uses machine learning algorithms to diagnose respiratory diseases from cough sounds recorded on a humble smartphone, achieved strong results that in some cases exceeded management’s expectations.
The Speedcast International Ltd (ASX: SDA) share price has jumped 6.5% higher to $4.52. This morning a change of director’s interest notice revealed that yet another of the company’s directors has been buying shares on-market after the recent collapse of its share price. According to today’s notice, Edward Sippel picked up 125,000 shares at an average price of $4.14. This follows no less than five other directors buying shares last week.
It's been a nail-biter of a reporting season here in the first half of 2018.
But the real action, in my opinion, is what companies are doing with dividends.
What does this mean for you? Well there is one stock I've found that could very well turn out to be THE best buy of 2018. And while there's no such thing as a 'sure thing' when it comes to investing - this ripper might come as close as I've ever seen.
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.